These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32346970)

  • 1. Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis.
    Furukawa M; Moriya K; Nakayama J; Inoue T; Momoda R; Kawaratani H; Namisaki T; Sato S; Douhara A; Kaji K; Kitade M; Shimozato N; Sawada Y; Saikawa S; Takaya H; Kitagawa K; Akahane T; Mitoro A; Yamao J; Tanaka Y; Yoshiji H
    Hepatol Res; 2020 Jul; 50(7):840-852. PubMed ID: 32346970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy.
    Tang R; Wei Y; Li Y; Chen W; Chen H; Wang Q; Yang F; Miao Q; Xiao X; Zhang H; Lian M; Jiang X; Zhang J; Cao Q; Fan Z; Wu M; Qiu D; Fang JY; Ansari A; Gershwin ME; Ma X
    Gut; 2018 Mar; 67(3):534-541. PubMed ID: 28213609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis.
    Chen W; Wei Y; Xiong A; Li Y; Guan H; Wang Q; Miao Q; Bian Z; Xiao X; Lian M; Zhang J; Li B; Cao Q; Fan Z; Zhang W; Qiu D; Fang J; Gershwin ME; Yang L; Tang R; Ma X
    Clin Rev Allergy Immunol; 2020 Feb; 58(1):25-38. PubMed ID: 30900136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut microbial profile of treatment-naive patients with primary biliary cholangitis.
    Zhou YJ; Ying GX; Dong SL; Xiang B; Jin QF
    Front Immunol; 2023; 14():1126117. PubMed ID: 37223092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiome pattern impacts treatment response in primary biliary cholangitis.
    Liu Q; Huang B; Zhou Y; Wei Y; Li Y; Li B; Li Y; Zhang J; Qian Q; Chen R; Lyu Z; Wang R; Cao Q; Xu Q; Wang Q; Miao Q; You Z; Lian M; Gershwin ME; Jin Q; Xiao X; Ma X; Tang R
    Med; 2024 Sep; ():. PubMed ID: 39305900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?
    Fukui H
    Diseases; 2019 Nov; 7(4):. PubMed ID: 31726747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy.
    Vespasiani-Gentilucci U; Rosina F; Pace-Palitti V; Sacco R; Pellicelli A; Chessa L; De Vincentis A; Barlattani M; Barlattani A; Feletti V; Mussetto A; Zolfino T; Russello M; Cozzolongo R; Garrucciu G; Niro G; Bacca D; Bertino G; Claar E; Ascione A; D'Adamo G; Adinolfi LE; Scifo G; Izzi A;
    Scand J Gastroenterol; 2019 Oct; 54(10):1274-1282. PubMed ID: 31564176
    [No Abstract]   [Full Text] [Related]  

  • 9. Evidence for the association between IgG-antimitochondrial antibody and biochemical response to ursodeoxycholic acid treatment in primary biliary cholangitis.
    Tang L; Zhong R; He X; Wang W; Liu J; Zhu Y; Li Y; Hou J
    J Gastroenterol Hepatol; 2017 Mar; 32(3):659-666. PubMed ID: 27529417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Machine learning-based characterization of the gut microbiome associated with the progression of primary biliary cholangitis to cirrhosis.
    Wang Q; Tang X; Qiao W; Sun L; Shi H; Chen D; Xu B; Liu Y; Zhao J; Huang C; Jin R
    Microbes Infect; 2024; 26(8):105368. PubMed ID: 38797428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis.
    Hao YL; Bian ZL; Ju LL; Liu Y; Qin G
    Dig Dis Sci; 2020 Feb; 65(2):470-479. PubMed ID: 31377883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.
    Samur S; Klebanoff M; Banken R; Pratt DS; Chapman R; Ollendorf DA; Loos AM; Corey K; Hur C; Chhatwal J
    Hepatology; 2017 Mar; 65(3):920-928. PubMed ID: 27906472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic success in primary biliary cholangitis and gut microbiota: a safe highway?
    Abenavoli L; Scarlata GG; Scarpellini E; Procopio AC; Ponziani FR; Boccuto L; Cetkovic N; Luzza F
    Minerva Gastroenterol (Torino); 2024 Dec; 70(4):430-441. PubMed ID: 38240684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic cholestatic diseases.
    Poupon R; Chazouillères O; Poupon RE
    J Hepatol; 2000; 32(1 Suppl):129-40. PubMed ID: 10728800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis.
    Ni P; Men R; Shen M; Wang T; Huang C; Fan X; Yang L
    Can J Gastroenterol Hepatol; 2019; 2019():7396870. PubMed ID: 31275901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct signatures of gut microbiota and metabolites in primary biliary cholangitis with poor biochemical response after ursodeoxycholic acid treatment.
    Han W; Song T; Huang Z; Liu Y; Xu B; Huang C
    Cell Biosci; 2024 Jun; 14(1):80. PubMed ID: 38879547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis.
    Honda A; Tanaka A; Kaneko T; Komori A; Abe M; Inao M; Namisaki T; Hashimoto N; Kawata K; Takahashi A; Ninomiya M; Kang JH; Arakawa M; Yamagiwa S; Joshita S; Umemura T; Sato K; Kaneko A; Kikuchi K; Itakura J; Nomura T; Kakisaka K; Fujii H; Kawada N; Takikawa Y; Masaki T; Ohira H; Mochida S; Yoshiji H; Iimuro S; Matsuzaki Y; Takikawa H;
    Hepatology; 2019 Dec; 70(6):2035-2046. PubMed ID: 30737815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut Microbial Profile Changes in Patients with Gallbladder Stones after UDCA/CDCA Treatment.
    Lee J; Lee S; Kim H; Bae J; Park JS
    Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979756
    [No Abstract]   [Full Text] [Related]  

  • 19. Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis.
    Joshita S; Umemura T; Yamashita Y; Sugiura A; Yamazaki T; Fujimori N; Matsumoto A; Tanaka E
    Hepatol Res; 2019 Oct; 49(10):1236-1243. PubMed ID: 31077509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of primary biliary cholangitis prior to obeticholic acid availability.
    Durazzo M; Bonetto S; Fagoonee S; Morgando A; Pellicano R
    Minerva Med; 2018 Dec; 109(6):410-417. PubMed ID: 30022645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.